Objective -To examine the efficacy of cytopathology laboratories in monitoring action following an abnormal cervical smear. Setting -11 screening laboratories serving 19 districts in the former North Western region of the United Kingdom. Method -944 validated cases were identified at 11 laboratories. The screening history for each abnormal smear was obtained from the screening laboratory and compared with the records from the relevant family health services authority (FHSA) database. Results -Laboratories held com.plete follow up records in 740 (78·4%) cases; the FHSA records extended this to 910 (96·4%) cases. Poor communication was the main problem; computerisation was not neces-sary to improve fail-safe procedures. Conclusions -Audit offail-safe procedures is a valuable purchasing tool, identifying weaknesses and strengths, setting and maintaining standards.
For cervical screening to be effective, women with abnormal smears must receive appropriate follow up. As part of the United Kingdom cervical screening programme the "fail-safe mechanism" defines each agency's responsibilities in ensuring that follow up is carried out. Although fail-safe arrangements vary locally, cytopathology laboratories are expected to play an important part by maintaining a register of abnormal smears screened, monitoring subsequent follow up (for example, repeat smears, histology reports), and initiating investigation when no follow up is carried out."? There does not seem to be published research on how successfully laboratories are meeting this requirement. This is a cause for concern, particularly as research undertaken before the introduction of the call/recall system suggested that fail-safe procedures in the north west and elsewhere were flawed.:"
The results reported here form part of a wider retrospective study of fail-safe mechanisms in the north west begun in 1992. At that time all the screening laboratories claimed to operate in accordance with national guidelines on failsafe procedures, but there was considerable variation in the way the systems were organised in practice (such as computerised or manual)."
Methods
Eleven main screening laboratories serve 19 districts in the former North Western region. It was thought that fail-safe management would vary by laboratory, district, and the degree of cytological abnormality. The sample thus comprised 25 sequential cases with moderate dyskaryosis and 25 sequential cases with severe dyskaryosis or invasive disease from 1 January 1991 for each district of residence. A total of 944 validated cases were identified at the 11 laboratories. In districts where two laboratories took a significant share of smear workload, cases were collected from both laboratories until the district quota (for residents) was reached. Consequently, the number of cases for each laboratory varied. The subsequent screening history for each woman in the sample was obtained from the screening laboratory and updated from the database held by the relevant family health services authorities (FHSAs). The available follow up time varied because of the sequential nature of the sample. In 919 (97%) cases at least 12 months had passed since the index smear was taken before the audit team examined the laboratory's records. (The minimum period available for follow up was nine months -four cases.)
Results
Overall, the laboratories held a complete record offollow up in 740 (78'4%) cases. In a further 23 (2'4%) cases partial information was held about follow up. Thus, for example, a referral had been noted or fail-safe actions had been instigated -the laboratory had sent a letter to a woman's general practitioner requesting information about her follow up and were waiting for a response. In 181 (19'2%) cases no follow up information was recorded at the laboratory.
The FHSA records extended coverage to 910 (96'4%) cases. Laboratories were rarely aware of this. In fact, in 35 (3'7%) cases the laboratory and FHSA records conflicted in some way -for example, over the woman's general practitioner or address. In one case the laboratory had notified the director of public health that a woman had been lost to follow up while the FHSA simultaneously held records of her follow up smears.
There was variation in performance by laboratory and district of residence. Six laboratories held complete or partial information for 90% or more of their cases (see figure) . Laboratories A, B, and E were smaller laboratories 
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The percentage of cases identified at each cytopathology laboratory for which some information on follow up was retrieved from the laboratory and the family health services authority (FHSA). There was variation in the results at local level and the FHSAs were the only source of follow up information for a considerablepercentage of cases -15% overall. Numbers are small for laboratories A and G.
operating good manual systems, laboratories C and F had computerised fail-safe procedures, and laboratory D had access to the FHSA records. In laboratory K the audit team was only able to retrieve follow up details for 13 (25%) of its 51 cases; the policy of this laboratory at the time of the audit was to follow up severe cases only.
Laboratory J offered a centralised screening service and received around 40% of all routine smears in the North Western region. It was a principal screener for 11 districts. This laboratory had a computerised fail-safe system but only had complete records for 79% of cases.
When the cases in laboratory Jwere categorised by district of residence, completeness of follow up varied from 94% to 50%, largely because histology tends to be done in the district of residence and there were sometimes difficulties obtaining these reports.
Discussion
Recording follow up is a necessary prerequisite for an effective fail-safe procedure and this in turn, for an effective screening programme. The cytopathology laboratories are uniquely placed to undertake this task because they routinely receive biopsy information for those women referred for further investigation -information required for the laboratory's quality control checks. It is clear that over 90% follow up is possible and that computerisation is not necessary to achieve this. Laboratories with less follow up are performing sub optimally, and their performance needs improvement. A named individual in each laboratory, responsible for monitoring follow up, and ensuring, for example, a prompt response to requests for biopsy information, should be a priority. Making these improvements may have resource implications.
In many districts laboratory and FHSA failsafe systems have tended to operate independently, leading to duplicated effort. Better communication between laboratories and FHSAs could improve the situation and should be included in national guidelines. Purchasers are ideally placed to take the lead in specifying and integrating fail-safe standards. This is particularly important where screening is purchased from several laboratories.
The results of this audit have informed the purchase of screening in the north west and set standards by which performance might be monitored. The method of this audit could be used for monitoring because it records the contribution from the screening laboratory, the FHSA, and local treatment services (for histology). All will require feedback if the audit loop is to be closed and service improvements recorded. Introduction of the internal market is prompting more cytology laboratories to offer screening services in the north west; in such a dynamic environment effective continuous monitoring of such services must be a priority. Purchasers' performance should be judged by the means of securing adequate fail-safe mechanisms through the contracting process.
